Abstract
Acute liver injury (ALI) is a life-threatening condition characterized by rapid hepatocyte death and systemic inflammation. This study investigates the protective effects of curcumin, a polyphenol derived from Curcuma longa, against ALI induced by lipopolysaccharide (LPS) and D-galactosamine (D-GalN). Using both in vitro L-02 cell models and in vivo Sprague-Dawley rat models, researchers demonstrated that curcumin significantly reduces liver damage, oxidative stress, and inflammatory cell death (pyroptosis) by downregulating the TLR4/NF-кB/NLRP3 signaling axis.
Introduction
Acute liver injury (ALI) often results from drug toxicity, sepsis, or excessive alcohol consumption, leading to high mortality rates due to rapid liver failure. A central mechanism in ALI is the activation of the NLRP3 inflammasome, which triggers the release of pro-inflammatory cytokines and initiates pyroptosis—a form of programmed, inflammatory cell death. Curcumin has long been recognized for its anti-inflammatory and antioxidant properties. This research aims to elucidate the specific molecular mechanisms by which curcumin mitigates ALI, focusing on the TLR4/NF-кB/NLRP3 signaling pathway.
Materials and Methods
The study utilized a dual-model approach to validate curcumin's efficacy:
- In Vitro Model: Human L-02 liver cells were treated with 10 μg/mL LPS to induce injury. Curcumin was applied at concentrations of 2.5, 5, and 10 μM, with Dexamethasone serving as a positive control.
- In Vivo Model: Male Sprague-Dawley rats received intraperitoneal injections of 0.02 mg/kg LPS and 500 mg/kg D-GalN. Curcumin was administered orally at doses of 50, 100, and 200 mg/kg, while Bifendate was used as a clinical control.
Assessment techniques included biochemical assays for liver enzymes (ALT, AST) and oxidative stress markers (MDA, SOD, CAT), histopathological analysis via H&E staining, and molecular quantification of protein and mRNA levels using Western blotting and qPCR.
Results
Attenuation of Liver Damage and Oxidative Stress
In the rat model, LPS/D-GalN administration caused a sharp rise in serum ALT and AST levels, indicating severe hepatocyte damage. Curcumin treatment, particularly at the 200 mg/kg dose, significantly lowered these enzymes. Furthermore, curcumin restored the antioxidant balance by increasing Superoxide Dismutase (SOD) and Catalase (CAT) activities while reducing Malondialdehyde (MDA) levels, a marker of lipid peroxidation.
Inhibition of the TLR4/NF-кB/NLRP3 Axis
Molecular analysis revealed that curcumin effectively suppressed the TLR4/NF-кB/NLRP3 signaling chain. By inhibiting TLR4 (the sensor), curcumin prevented the nuclear translocation of NF-кB (the messenger), which is necessary for the transcription of NLRP3 inflammasome components. Consequently, the expression of NLRP3, Caspase-1, and the pyroptosis executioner protein GSDMD was significantly reduced in both cell and animal models.
Histopathological Improvements
Microscopic examination of liver tissues from the model group showed extensive necrosis, congestion, and inflammatory cell infiltration. Curcumin treatment preserved the structural integrity of hepatic lobules and markedly reduced these pathological changes, confirming its protective role at the tissue level. In the L-02 cell model, curcumin treatment restored cell viability from 80% in the LPS group to nearly 100%.
Discussion
The findings suggest that curcumin acts as a multi-level inhibitor of the inflammatory response in ALI. By targeting the TLR4/NF-кB/NLRP3 pathway, curcumin not only reduces the production of inflammatory cytokines but also prevents the catastrophic cell death associated with pyroptosis. While the poor bioavailability of curcumin remains a challenge for clinical translation, these results provide a strong mechanistic basis for its potential use as a therapeutic agent for acute liver failure.
Conclusion
Curcumin ameliorates LPS/D-GalN-induced acute liver injury by inhibiting the TLR4/NF-кB/NLRP3 signaling pathway and reducing oxidative stress. These results highlight curcumin's potential as a protective agent against inflammatory liver diseases and provide a foundation for future clinical investigations.
Summary updated